Pictet Asset Management Holding SA Has $51.53 Million Holdings in DexCom, Inc. (NASDAQ:DXCM)

Pictet Asset Management Holding SA reduced its stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 1.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 662,619 shares of the medical device company's stock after selling 10,420 shares during the quarter. Pictet Asset Management Holding SA owned about 0.17% of DexCom worth $51,532,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of the stock. Forvis Mazars Wealth Advisors LLC increased its stake in DexCom by 0.7% during the 4th quarter. Forvis Mazars Wealth Advisors LLC now owns 17,481 shares of the medical device company's stock valued at $1,359,000 after buying an additional 118 shares during the period. Principal Securities Inc. increased its stake in shares of DexCom by 3.4% during the fourth quarter. Principal Securities Inc. now owns 4,069 shares of the medical device company's stock valued at $316,000 after acquiring an additional 135 shares during the period. Larson Financial Group LLC raised its holdings in DexCom by 40.5% during the fourth quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock worth $37,000 after purchasing an additional 137 shares in the last quarter. TD Private Client Wealth LLC raised its holdings in DexCom by 62.8% during the fourth quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock worth $34,000 after purchasing an additional 167 shares in the last quarter. Finally, GPS Wealth Strategies Group LLC lifted its position in DexCom by 13.2% in the fourth quarter. GPS Wealth Strategies Group LLC now owns 1,587 shares of the medical device company's stock worth $123,000 after purchasing an additional 185 shares during the period. Institutional investors and hedge funds own 97.75% of the company's stock.

Analysts Set New Price Targets

A number of analysts have recently commented on DXCM shares. Baird R W raised DexCom from a "hold" rating to a "strong-buy" rating in a research note on Thursday, January 16th. Morgan Stanley boosted their price target on shares of DexCom from $75.00 to $82.00 and gave the stock an "equal weight" rating in a research report on Friday, February 14th. Robert W. Baird upgraded shares of DexCom from a "neutral" rating to an "outperform" rating and raised their price objective for the company from $86.00 to $104.00 in a research report on Thursday, January 16th. Wells Fargo & Company reiterated an "overweight" rating on shares of DexCom in a report on Saturday, March 8th. Finally, Canaccord Genuity Group increased their target price on shares of DexCom from $99.00 to $103.00 and gave the company a "buy" rating in a research note on Friday, February 14th. Five analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $99.82.

DexCom Stock Down 8.7 %

Shares of DexCom stock traded down $5.90 during midday trading on Thursday, hitting $62.24. The company's stock had a trading volume of 1,724,552 shares, compared to its average volume of 4,059,440. The firm has a market capitalization of $24.32 billion, a P/E ratio of 43.52, a PEG ratio of 2.30 and a beta of 1.28. DexCom, Inc. has a 1-year low of $61.79 and a 1-year high of $141.99. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59. The stock has a 50-day simple moving average of $81.24 and a 200-day simple moving average of $77.04.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing analysts' consensus estimates of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. As a group, sell-side analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current year.

Insiders Place Their Bets

In other DexCom news, COO Jacob Steven Leach sold 14,076 shares of the company's stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total value of $990,668.88. Following the transaction, the chief operating officer now directly owns 313,497 shares of the company's stock, valued at $22,063,918.86. This represents a 4.30 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Kevin R. Sayer sold 32,498 shares of DexCom stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total value of $2,287,209.24. Following the sale, the chief executive officer now owns 372,029 shares of the company's stock, valued at approximately $26,183,401.02. This represents a 8.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 105,009 shares of company stock worth $8,044,178 in the last quarter. 0.30% of the stock is currently owned by corporate insiders.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.